Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hims and Hers Health Inc (HIMS) vs Workiva Inc (WK) Price & Performance

Hims and Hers Health IncTrade
Workiva IncTrade

Price performance (Past 24H)

Key statistics

Hims and Hers Health Inc vs Workiva Inc — how do they compare? Hims and Hers Health Inc trades at $31.09 (market cap $6.55B), while Workiva Inc trades at $73.27 (market cap $4.01B). The key difference: Hims and Hers Health Inc is the larger of the two by market cap, and Workiva Inc is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Workiva Inc for 21 Days on average.

HIMSWK
Market Cap
$6.55B$4.01B
Volume
14,842,8141,301,708
Sector
HealthTechnology
52-Week High
$62.76$93.31
52-Week Low
$14.52$44.31
Typical Hold Time
21 Days21 Days
Enterprise Value
$7.25B$3.99B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hims and Hers Health Inc

Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.

The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.

Workiva Inc

Workiva (WK) trades at $73.20, up 2.33% with bullish technical indicators and strong analyst support. The company shows improving fundamentals with revenue growth from $885M to $966M and a shift from a $26M loss to $47M profit in 2026. Recent product innovations in AI and regulatory platforms highlight business momentum, supported by consistent earnings beats in recent quarters.

Outlook remains positive with 89% analyst buy ratings and $86 consensus target offering 17% upside. Key risks include high valuation multiples (P/E 87.7) and competitive pressures in regulatory technology. The stock's technical strength and fundamental improvement suggest continued growth potential, though investors should monitor execution on profitability targets.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HIMS
89% Buy11% Sell
Avg holding period · 21 Days
WK
0% Buy100% Sell
Avg holding period · 21 Days

About Hims and Hers Health Inc

Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.

Read more on HIMS →

About Workiva Inc

Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.

Read more on WK →